Oral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal Bevacizumab

• Status: Completed
• Trial end date: 2009-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effects of anterior chamber paracentesis, brimonidine and oral acetazolamide to reduce intra-ocular pressure variations after intravitreal bevacizumab injection.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Sao Paulo
• Collaborator: Fundação de Apoio ao Ensino Pesquisa e Assitência do HCFMRPUSP
• Treatments: Acetazolamide; Bevacizumab; Brimonidine Tartrate

Criteria

Inclusion Criteria:

• Diagnosis of age related macular disease or diabetic retinopathy

• Able and willing to provide informed consent

Exclusion Criteria:

• History of ocular hypertension or glaucoma

• High Myopes (> 6 spherical diopters)

• High Hyperopes (> 4 spherical diopters)

• Pulmonary disease

• Renal disease

• Known allergy to any component of the study drug

• Myocardial infarction, transient ischemic attack within 4 months prior to randomization or any contraindication for bevacizumab use